Client News

Rentschler Biopharma adds highly experienced executive to team and provides update on progress at Rentschler ATMP

DEBx Medical: Debrichem / NHS: Significant cost-effectiveness and better outcomes in VLUs, as published in Journal of Wound Care

Abivax releases the results of its June 9, 2022 ordinary annual and extraordinary general meeting

Andera Partners co-leads $118 Million Oversubscribed Series B Financing of Mineralys Therapeutics to Advance the Development of Novel, Targeted Treatment for Hypertension

Newron presents encouraging interim results for evenamide in patients with Treatment-Resistant Schizophrenia (TRS) at the 33rd CINP Hybrid World Congress of Neuropsychopharmacology

LINDIS Biotech Announces Online Publication of Abstract on Trifunctional Antibody CATUMAXOMAB for the Treatment of HighRisk Non-Muscle-Invasive Bladder Cancer at the ASCO 2022 Annual Meeting

Abivax phase 2a study results of obefazimod (ABX464) in rheumatoid arthritis published in the journal “Annals of the Rheumatic Diseases” and selected for presentation at EULAR 2022

First subject dosed in Lipigon’s phase I clinical study with antisense oligonucleotide candidate derived from Secarna Pharmaceutical’s LNAplus™ technology platform

Galapagos Biopharma: Vom Labor zum Patienten – vom Start-up zum Biopharmaunternehmen

Destiny Pharma plc: Result of Annual General Meeting and Strategy Update